日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment

CREB3L1促进胰腺肿瘤进展,并重编程肿瘤内肿瘤相关巨噬细胞,从而形成免疫治疗耐药的微环境。

Xu, Haiyan; Xue, Shengbai; Sun, Yang; Ma, Jingyu; Li, Shumin; Wang, Yanling; Mao, Tiebo; Ge, Weiyu; Yue, Ming; Shentu, Daiyuan; Lu, Wenxin; Wang, Yongchao; Hu, Jiong; Cui, Jiujie; Zhang, Xiaofei; Cai, Li; Wang, Yu; Wang, Liwei

Targeted therapies and immunotherapies for unresectable cholangiocarcinoma

针对无法切除的胆管癌的靶向治疗和免疫疗法

Xue, Shengbai; Jiang, Weihua; Ma, Jingyu; Xu, Haiyan; Wang, Yanling; Lu, Wenxin; Shentu, Daiyuan; Cui, Jiujie; Li, Maolan; Wang, Liwei

Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial

舒鲁替尼联合紫杉醇作为晚期胃癌二线治疗:一项单臂 II 期临床试验

Han, Ting; Zhuo, Meng; Zheng, Xinyi; Wu, Xiuqi; Jiao, Feng; Cui, Jiujie; Wang, Tao; Qiu, Xiaoxia; Su, Yingjie; Lin, Xiaolin; Xiao, Xiuying

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial

伊立替康盐酸盐脂质体 HR070803 联合 5-氟尿嘧啶和亚叶酸钙治疗既往接受过吉西他滨治疗的局部晚期或转移性胰腺导管腺癌(PAN-HEROIC-1):一项 3 期试验

Cui, Jiujie; Qin, Shukui; Zhou, Yuhong; Zhang, Shuang; Sun, Xiaofeng; Zhang, Mingjun; Cui, Jiuwei; Fang, Weijia; Gu, Kangsheng; Li, Zhihua; Wang, Jufeng; Chen, Xiaobing; Yao, Jun; Zhou, Jun; Wang, Gang; Bai, Yuxian; Xiao, Juxiang; Qiu, Wensheng; Wang, Bangmao; Xia, Tao; Wang, Chunyue; Kong, Li; Yin, Jiajun; Zhang, Tao; Shen, Xionghu; Fu, Deliang; Gao, Chuntao; Wang, Huan; Wang, Quanren; Wang, Liwei

Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms

中华医学会关于胰腺神经内分泌肿瘤规范化诊疗的共识

Jiao, Feng; Cui, Jiujie; Fu, Deliang; Li, Qi; Wu, Zheng; Teng, Zan; Zhang, Hongmei; Zhou, Jun; Zhang, Zhihong; Chen, Xiaobing; Zhou, Yuhong; Li, Yixiong; Mou, Yiping; Qin, Renyi; Sun, Yongwei; Jin, Gang; Cheng, Yuejuan; Wang, Jian; Ren, Gang; Yue, Jiang; Jin, Guangxin; Xiao, Xiuying; Wang, Liwei

Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients

铜凋亡相关长链非编码RNA与肿瘤代谢和免疫微环境相关,并可预测胰腺癌患者的预后

Wang, Yanling; Ge, Weiyu; Xue, Shengbai; Cui, Jiujie; Zhang, Xiaofei; Mao, Tiebo; Xu, Haiyan; Li, Shumin; Ma, Jingyu; Yue, Ming; Shentu, Daiyuan; Wang, Liwei

Characterization of DNA damage response deficiency in pancreatic cancer patients from China

中国胰腺癌患者DNA损伤反应缺陷的特征分析

Zhang, Xiaofei; Mao, Tiebo; Zhang, Bei; Xu, Haiyan; Cui, Jiujie; Jiao, Feng; Chen, Dongqin; Wang, Yu; Hu, Jiong; Xia, Qing; Li, Shumin; Yue, Ming; Ma, Jingyu; Yao, Jiayu; Wang, Yongchao; Zhang, Xiao; Chen, Shiqing; Bai, Yuezong; Wang, Yuexiang; Zhang, Xuebin; Liu, Qiang; Sun, Yongwei; Fu, Deliang; Liu, Yingbin; Xiong, Lei; Wang, Liwei

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer

对中国胰腺癌患者的大规模基因组图谱进行表征

Zhang, Xiaofei; Mao, Tiebo; Zhang, Bei; Xu, Haiyan; Cui, Jiujie; Jiao, Feng; Chen, Dongqin; Wang, Yu; Hu, Jiong; Xia, Qing; Ge, Weiyu; Li, Shumin; Yue, Ming; Ma, Jingyu; Yao, Jiayu; Wang, Yongchao; Wang, Yanling; Shentu, Daiyuan; Zhang, Xiao; Chen, Shiqing; Bai, Yuezong; Wang, Yuexiang; Zhang, Xuebin; Liu, Qiang; Sun, Yongwei; Fu, Deliang; Liu, Yingbin; Xiong, Lei; Wang, Liwei

Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer

中国临床肿瘤学会(CSCO):胰腺癌诊疗临床指南

Cui, Jiujie; Jiao, Feng; Li, Qi; Wang, Zheng; Fu, Deliang; Liang, Jun; Liang, Houjie; Xia, Tingyi; Zhang, Tao; Zhang, Yang; Dai, Guanghai; Zhang, Zhihong; Wang, Jian; Bai, Yongrui; Bai, Yuxian; Bi, Feng; Chen, Donghui; Cao, Dan; Chen, Jie; Fang, Weijia; Gao, Yong; Guo, Jianwei; Hao, Jihui; Hua, Haiqing; Huang, Xinyu; Liu, Wenchao; Liu, Xiufeng; Li, Da; Li, Ji; Li, Enxiao; Li, Zhiwei; Pan, Hongming; Shen, Lin; Sun, Yongwei; Tao, Min; Wang, Chengfeng; Wang, Fenghua; Xiong, Jianping; Zhang, Taiping; Zhang, Xuebin; Zhan, Xianbao; Zheng, Leizhen; Ren, Gang; Zhang, Tingting; Zhou, Jun; Ma, Qingyong; Qin, Shukui; Hao, Chunyi; Wang, Liwei

HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53

HDACs/mTOR抑制剂通过降解突变型P53与吡咯替尼在HER2阳性胰腺癌中发挥协同作用

Mao, Tiebo; Zhang, Xiaofei; Xu, Haiyan; Zhang, Xiao; Ge, Weiyu; Li, Shumin; Ma, Jingyu; Yue, Ming; Xue, Shengbai; Cui, Jiujie; Wang, Liwei